Tirzepatide
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
Eli Lilly · Phase 2 · Recruiting · Enrollment 372
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| HDM1005 injection dose group 1 | n/r | n/r | n/r | n/r | n/r |
| HDM1005 injection dose group 2 | n/r | n/r | n/r | n/r | n/r |
| HDM1005 injection dose group 3 | n/r | n/r | n/r | n/r | n/r |
| tirzepatide injection | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.